TG Therapeutics Inc
TGTX31.070USD
+0.340+1.11%
Close 12/24, 16:00（ET）Quotes delayed by 15 min
4.82BMarket Cap
10.15P/E TTM
More Details of TG Therapeutics Inc Company
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
TG Therapeutics Inc Info
Ticker SymbolTGTX
Company nameTG Therapeutics Inc
IPO dateDec 14, 1995
CEOWeiss (Michael S)
Number of employees338
Security typeOrdinary Share
Fiscal year-endDec 14
Address3020 Carrington Mill Blvd., Suite 475
CityMORRISVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27560-5435
Phone18775758489
Websitehttps://www.tgtherapeutics.com/
Ticker SymbolTGTX
IPO dateDec 14, 1995
CEOWeiss (Michael S)
Company Executives of TG Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.16M
-33.77%
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
-2.19%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
-18.15%
Name
Name/Position
Position
Shareholding
Change
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.16M
-33.77%
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
-2.19%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q1
FY2024
By BusinessUSD
Name
Revenue
Proportion
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.86%
The Vanguard Group, Inc.
9.75%
Weiss (Michael S)
5.77%
State Street Investment Management (US)
5.10%
ClearBridge Investments, LLC
2.93%
Other
64.59%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.86%
The Vanguard Group, Inc.
9.75%
Weiss (Michael S)
5.77%
State Street Investment Management (US)
5.10%
ClearBridge Investments, LLC
2.93%
Other
64.59%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.37%
Investment Advisor/Hedge Fund
17.35%
Hedge Fund
7.07%
Individual Investor
6.78%
Research Firm
3.06%
Pension Fund
1.30%
Bank and Trust
0.39%
Family Office
0.13%
Sovereign Wealth Fund
0.06%
Other
29.49%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
698
101.46M
63.91%
-17.24M
2025Q2
693
115.94M
73.03%
-21.56M
2025Q1
704
116.82M
73.80%
-25.76M
2024Q4
657
113.87M
72.65%
-36.14M
2024Q3
598
117.83M
76.11%
-20.28M
2024Q2
544
109.58M
70.90%
-28.91M
2024Q1
535
105.41M
68.45%
-29.01M
2023Q4
542
104.64M
69.13%
-36.73M
2023Q3
552
104.67M
69.33%
-30.54M
2023Q2
543
102.45M
68.58%
-35.33M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
19.13M
12.06%
-84.56K
-0.44%
Jun 30, 2025
The Vanguard Group, Inc.
15.77M
9.94%
+203.00K
+1.30%
Jun 30, 2025
Weiss (Michael S)
13.82M
8.71%
--
--
Apr 14, 2025
State Street Investment Management (US)
7.62M
4.8%
+184.34K
+2.48%
Jun 30, 2025
ClearBridge Investments, LLC
3.05M
1.92%
+408.10K
+15.43%
Jun 30, 2025
Soleus Capital Management, L.P.
2.24M
1.41%
-602.77K
-21.17%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.49M
2.2%
+207.89K
+6.33%
Jun 30, 2025
Pictet Asset Management Ltd.
1.91M
1.2%
-489.69K
-20.43%
Jun 30, 2025
Hood River Capital Management LLC
1.57M
0.99%
+11.02K
+0.71%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco S&P SmallCap Health Care ETF
2.89%
State Street SPDR S&P Biotech ETF
1.93%
Virtus LifeSci Biotech Products ETF
1.49%
Invesco S&P SmallCap 600 Pure Growth ETF
1.44%
Invesco S&P SmallCap Momentum ETF
1.4%
Direxion Daily S&P Biotech Bull 3X Shares
1.11%
State Street SPDR S&P 600 Small Cap Growth ETF
0.65%
First Trust NASDAQ Pharmaceuticals ETF
0.63%
Principal U.S. Small-Cap ETF
0.62%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.61%
View more
Invesco S&P SmallCap Health Care ETF
Proportion2.89%
State Street SPDR S&P Biotech ETF
Proportion1.93%
Virtus LifeSci Biotech Products ETF
Proportion1.49%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.44%
Invesco S&P SmallCap Momentum ETF
Proportion1.4%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.11%
State Street SPDR S&P 600 Small Cap Growth ETF
Proportion0.65%
First Trust NASDAQ Pharmaceuticals ETF
Proportion0.63%
Principal U.S. Small-Cap ETF
Proportion0.62%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0.61%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of TG Therapeutics Inc?
The top five shareholders of TG Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A. holds 19.13M shares, accounting for 12.06% of the total shares.
The Vanguard Group, Inc. holds 15.77M shares, accounting for 9.94% of the total shares.
Weiss (Michael S) holds 13.82M shares, accounting for 8.71% of the total shares.
State Street Investment Management (US) holds 7.62M shares, accounting for 4.80% of the total shares.
ClearBridge Investments, LLC holds 3.05M shares, accounting for 1.92% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 19.13M shares, accounting for 12.06% of the total shares.
The Vanguard Group, Inc. holds 15.77M shares, accounting for 9.94% of the total shares.
Weiss (Michael S) holds 13.82M shares, accounting for 8.71% of the total shares.
State Street Investment Management (US) holds 7.62M shares, accounting for 4.80% of the total shares.
ClearBridge Investments, LLC holds 3.05M shares, accounting for 1.92% of the total shares.
What are the top three shareholder types of TG Therapeutics Inc?
The top three shareholder types of TG Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Weiss (Michael S)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Weiss (Michael S)
How many institutions hold shares of TG Therapeutics Inc (TGTX)?
As of 2025Q3, 698 institutions hold shares of TG Therapeutics Inc, with a combined market value of approximately 101.46M, accounting for 63.91% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.12%.
What is the biggest source of revenue for TG Therapeutics Inc?
In FY2025Q1, the Total product revenue, net business generated the highest revenue for TG Therapeutics Inc, amounting to 119.66M and accounting for 99.01% of total revenue.
